The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Suliman, H. B., Carraway, M. S., Ali, A. S., Reynolds, C. M., Welty-Wolf, K. E., & Piantadosi, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32967 · Cited by 257
RetractedMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Superoxide radical and superoxide dismutases
Fridovich, I. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000525 · Cited by 3,455
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
Li, Y., Huang, T.-T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-376 · Cited by 1,789
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72931 · Cited by 878
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
Olson, R. D., & Mushlin, P. S. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.13.2210154 · Cited by 690
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation
Erickson, J. R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., Copeland, R. J., Despa, F., Hart, G. W., Ripplinger, C. M., et al. (2013) · Nature · doi:10.1038/nature12537 · Cited by 598
Mitochondrial Energetics in the Heart in Obesity-Related Diabetes
Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J. J., Hu, X. X., Aziz, S., Johnson, J. I., Bugger, H., Zaha, V. G., et al. (2007) · Diabetes · doi:10.2337/db07-0481 · Cited by 586
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Piantadosi, C. A., Carraway, M. S., Babiker, A., & Suliman, H. B. (2008) · Circulation Research · doi:10.1161/01.res.0000338597.71702.ad · Cited by 578
Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure
Chen, J.-F., Murchison, E. P., Tang, R., Callis, T. E., Tatsuguchi, M., Deng, Z., Rojas, M., Hammond, S. M., Schneider, M. D., Selzman, C. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710228105 · Cited by 576
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Childs, A. C., Phaneuf, S., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002) · PubMed · Cited by 525
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
Mazumder, P. K., O’Neill, B. T., Roberts, M. W., Buchanan, J., Yun, U. J., Cooksey, R. C., Boudina, S., & Abel, E. D. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2366 · Cited by 437
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Myocyte Death in the Failing Human Heart Is Gender Dependent
Guerra, S., Leri, A., Wang, X., Finato, N., Di Loreto, C., Beltrami, C. A., Kajstura, J., & Anversa, P. (1999) · Circulation Research · doi:10.1161/01.res.85.9.856 · Cited by 417
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
Doxorubicin‐Induced Cardiac Mitochondrionopathy
Wallace, K. B. (2003) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2003.930301.x · Cited by 389
Zhao, L., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep44735 · Cited by 375
Eom, Y.-W., Kim, M. A., Park, S. S., Goo, M. J., Kwon, H. J., Sohn, S., Kim, W.-H., Yoon, G., & Choi, K. S. (2005) · Oncogene · doi:10.1038/sj.onc.1208627 · Cited by 351
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Doxorubicin induced heart failure: Phenotype and molecular mechanisms
Mitry, M. A., & Edwards, J. G. (2016) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2015.11.004 · Cited by 311
Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation
Garcı́a, J. J., Reiter, R. J., Guerrero, J. M., Escames, G., Yu, B. P., Oh, C. S., & Muñoz-Hoyos, A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00447-x · Cited by 302
Kim, S.-Y., Kim, S.-J., Kim, B.-J., Rah, S.-Y., Chung, S. M., Im, M.-J., & Kim, U.-H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.63 · Cited by 297
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., & Nemer, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401833101 · Cited by 296
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
Apoptosis is Initiated by Myocardial Ischemia and Executed During Reperfusion
Freude, B., Masters, T. N., Robicsek, F., Fokin, A., Kostin, S., Zimmermann, R., Ullmann, C., Lorenz-Meyer, S., & Schaper, J. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1999.1066 · Cited by 289
WANG, S., KOTAMRAJU, S., KONOREV, E., KALIVENDI, S., JOSEPH, J., & KALYANARAMAN, B. (2002) · Biochemical Journal · doi:10.1042/bj20020752 · Cited by 286
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995) · Circulation · doi:10.1161/01.cir.91.1.10 · Cited by 285
Role of TLR-2 in the Activation of Nuclear Factor κB by Oxidative Stress in Cardiac Myocytes
Frantz, S., Kelly, R. A., & Bourcier, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009160200 · Cited by 266
Autophagy in cardiac myocyte homeostasis, aging, and pathology
TERMAN, A., & BRUNK, U. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.014 · Cited by 266
Liu, J., Mao, W., Ding, B., & Liang, C.-S. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00407.2008 · Cited by 255
Life in the balance – a mechanistic view of the crosstalk between autophagy and apoptosis
Rubinstein, A. D., & Kimchi, A. (2012) · Journal of Cell Science · doi:10.1242/jcs.115865 · Cited by 249
Increased Myocardial Oxygen Consumption Reduces Cardiac Efficiency in Diabetic Mice
How, O.-J., Aasum, E., Severson, D. L., Chan, W. Y. A., Essop, M. F., & Larsen, T. S. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1164 · Cited by 248
Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone
Damiani, R. M., Moura, D. J., Viau, C. M., Caceres, R. A., Henriques, J. A. P., & Saffi, J. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1759-y · Cited by 247
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy
Bristow, M. R., Mason, J. W., Billingham, M. E., & Daniels, J. R. (1981) · American Heart Journal · doi:10.1016/0002-8703(81)90096-x · Cited by 245
Diabetes increases mortality after myocardial infarction by oxidizing CaMKII
Luo, M., Guan, X., Luczak, E. D., Lang, D., Kutschke, W., Gao, Z., Yang, J., Glynn, P., Sossalla, S., Swaminathan, P. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65268 · Cited by 240
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235
Maejima, Y., Adachi, S., Ito, H., Hirao, K., & Isobe, M. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00358.x · Cited by 224
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Mechanisms and management of doxorubicin cardiotoxicity
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011) · Herz · doi:10.1007/s00059-011-3470-3 · Cited by 215
Autophagic dysregulation in doxorubicin cardiomyopathy
Bartlett, J. J., Trivedi, P. C., & Pulinilkunnil, T. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.01.007 · Cited by 214
DNA damage is an early event in doxorubicin-induced cardiac myocyte death
L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Heide, R. V. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00738.2005 · Cited by 212
Mitochondrial dysfunction in diabetic cardiomyopathy
Duncan, J. G. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.014 · Cited by 208
Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, Y., Takanabe-Mori, R., Nishi, E., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq148 · Cited by 208
Kuznetsov, A. V., Margreiter, R., Amberger, A., Saks, V., & Grimm, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.002 · Cited by 207
Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice
Riad, A., Bien, S., Westermann, D., Becher, P. M., Loya, K., Landmesser, U., Kroemer, H. K., Schultheiss, H. P., & Tschöpe, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3076 · Cited by 205
Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., Gottlieb, R. A., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.902221 · Cited by 203
Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., & Cairo, G. (2001) · PubMed · Cited by 200
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti, F. M., Bristow, M. R., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., Brown, B. W., Hannigan, J. F., Meyers, F. J., & Mitchell, E. P. (1986) · PubMed · Cited by 197
Sauter, K. A. D., Wood, L. J., Wong, J., Iordanov, M., & Magun, B. E. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.12.15540 · Cited by 194
Sam, F., Sawyer, D. B., Chang, D. L.-F., Eberli, F. R., Ngoy, S., Jain, M., Amin, J., Apstein, C. S., & Colucci, W. S. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.1.h422 · Cited by 190
Ueno, M., Kakinuma, Y., Yuhki, K.-I., Murakoshi, N., Iemitsu, M., Miyauchi, T., & Yamaguchi, I. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0050980 · Cited by 189
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., & Suzuki, Y. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.368 · Cited by 188
Effects by doxorubicin on the myocardium are mediated by oxygen free radicals
Xu, M. F., Tang, P. L., Qian, Z. M., & Ashraf, M. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)00990-5 · Cited by 185
Nrf2 Deficiency Exaggerates Doxorubicin-Induced Cardiotoxicity and Cardiac Dysfunction
Li, S., Wang, W., Niu, T., Wang, H., Li, B., Shao, L., Lai, Y., Li, H., Janicki, J. S., Wang, X. L., et al. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/748524 · Cited by 183
SPALLAROSSA, P., ALTIERI, P., GARIBALDI, S., GHIGLIOTTI, G., BARISIONE, C., MANCA, V, FABBI, P., BALLESTRERO, A., BRUNELLI, C., & BARSOTTI, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.009 · Cited by 182
Andrieu‐Abadie, N., Jaffrézou, J., Hatem, S., Laurent, G., Levade, T., & Mercadier, J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1501 · Cited by 182
GOFFART, S., VONKLEISTRETZOW, J., & WIESNER, R. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.06.030 · Cited by 176
Cheung, K. G., Cole, L. K., Xiang, B., Chen, K., Ma, X., Myal, Y., Hatch, G. M., Tong, Q., & Dolinsky, V. W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607960 · Cited by 174
Kawaguchi, T., Takemura, G., Kanamori, H., Takeyama, T., Watanabe, T., Morishita, K., Ogino, A., Tsujimoto, A., Goto, K., Maruyama, R., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs282 · Cited by 172
Bristow, M. R., Sageman, W. S., Scott, R. H., Billingham, M. E., Bowden, R. E., Kernoff, R. S., Snidow, G. H., & Daniels, J. R. (1980) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198009000-00002 · Cited by 171
Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
Bayeva, M., Sawicki, K. T., & Ardehali, H. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000433 · Cited by 170
Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in Mice
Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., Kroemer, H. K., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.004 · Cited by 169
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., & Santos, M. M. (2003) · Blood · doi:10.1182/blood-2003-03-0869 · Cited by 168
Goormaghtigh, E., Chatelain, P., Caspers, J., & Ruysschaert, J. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90050-7 · Cited by 166
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Doxorubicin induces senescence and impairs function of human cardiac progenitor cells
Piegari, E., Angelis, A., Cappetta, D., Russo, R., Esposito, G., Costantino, S., Graiani, G., Frati, C., Prezioso, L., Berrino, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0334-4 · Cited by 163
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R., & Chua, B. H. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00759.2003 · Cited by 162
Ascensão, A., Magalhães, J., Soares, J. M. C., Ferreira, R., Neuparth, M. J., Marques, F., Oliveira, P. J., & Duarte, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01249.2004 · Cited by 160
Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
Tsai, Y.-T., Su, Y., Fang, S.-S., Huang, T.-N., Qiu, Y., Jou, Y., Shih, H.-M., Kung, H.-J., & Chen, R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2043-2054.2000 · Cited by 150
Fogli, S., Nieri, P., & Breschi, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0724rev · Cited by 149
Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury
Kobayashi, S., Xu, X., Chen, K., & Liang, Q. (2012) · Autophagy · doi:10.4161/auto.18980 · Cited by 147
Pani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., & Galeotti, T. (2000) · PubMed · Cited by 145
NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis
Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Nevière, R., & Lancel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.085 · Cited by 142
Sardão, V. A., Oliveira, P. J., Holy, J. M., Oliveira, C. R., & Wallace, K. B. (2008) · Cell Biology and Toxicology · doi:10.1007/s10565-008-9070-1 · Cited by 136
Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Pereira, G. C., Silva, A. M., Diogo, C. V., Carvalho, F. S., Monteiro, P. F., & Oliveira, P. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904812 · Cited by 136
Pointon, A., Walker, T. M., Phillips, K. M., Luo, J., Riley, J., Zhang, S., Parry, J. D., Lyon, J. J., Marczylo, E. L., & Gant, T. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012733 · Cited by 133
Davies, K. J. A., Doroshow, J. H., & Hochstein, P. E. (1983) · FEBS Letters · doi:10.1016/0014-5793(83)80153-7 · Cited by 132
Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy
Jeyaseelan, R., Poizat, C. I., Wu, H., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5828 · Cited by 131
Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure
Liu, F.-F., Stone, J. R., Schuldt, A. J. T., Okoshi, K., Okoshi, M. P., Nakayama, M., Ho, K. K. L., Manning, W. J., Marchionni, M. A., Lorell, B. H., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00268.2005 · Cited by 128
Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes
Sarvazyan, N. A. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.271.5.h2079 · Cited by 127
Jang, Y. M., Kendaiah, S., Drew, B., Phillips, T., Selman, C., Julian, D. A., & Leeuwenburgh, C. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.053 · Cited by 126
Gratia, S., Kay, L., Potenza, L., Seffouh, A., Novel-Chaté, V., Schnebelen, C., Sestili, P., Schlattner, U., & Tokarska-Schlattner, M. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs134 · Cited by 125
Caroni, P., Villani, F., & Carafoli, E. (1981) · FEBS Letters · doi:10.1016/0014-5793(81)81115-5 · Cited by 123
Cytoprotective agents for anthracyclines.
Rt, D. (1996) · PubMed · Cited by 119
Poizat, C. I., Puri, P., Bai, Y., & Kedes, L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2673-2687.2005 · Cited by 117
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
Iliskovic, N., & Singal, P. K. (1997) · Europe PMC (PubMed Central) · Cited by 114
Solem, L. E., Heller, L. J., & Wallace, K. B. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0095 · Cited by 111
Parker, M. A., King, V., & Howard, K. P. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00371-6 · Cited by 107
Pereira, R. O., Wende, A. R., Olsen, C. D., Soto, J. E., Rawlings, T. A., Zhu, Y., Anderson, S. M., & Abel, E. D. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000301 · Cited by 107
Singal, P. K., & Pierce, G. N. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.3.h419 · Cited by 105
Li, Z., Zhang, T., Dai, H., Liu, G., Wang, H., Sun, Y., Zhang, Y. L., & Ge, Z. (2007) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.2007008 · Cited by 103
Lakshmanan, A. P., Harima, M., Suzuki, K., Soetikno, V., Nagata, M., Nakamura, T., Takahashi, T., Sone, H., Kawachi, H., & Watanabe, K. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.09.017 · Cited by 100
Xu, J., Wang, G., Wang, Y., Liu, Q., Xu, W., Tan, Y., & Cai, L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00833.x · Cited by 100
Berthiaume, J. M., & Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0026-0 · Cited by 99
Xie, P., Guo, S., Fan, Y., Zhang, H., Gu, D., & Li, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806487200 · Cited by 99
Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment
Vacchi‐Suzzi, C., Bauer, Y., Berridge, B. R., Bongiovanni, S., Gerrish, K., Hamadeh, H. K., Letzkus, M., Lyon, J. J., Moggs, J. G., Paules, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040395 · Cited by 99
Doxorubicin cardiotoxicity and target cells: a broader perspective
Angelis, A. D., Urbanek, K., Cappetta, D., Piegari, E., Ciuffreda, L. P., Rivellino, A., Russo, R., Esposito, G., Rossi, F., & Berrino, L. (2016) · Cardio-Oncology · doi:10.1186/s40959-016-0012-4 · Cited by 98
Arunachalam, S., Pichiah, P. B. T., & Achiraman, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.11.019 · Cited by 96
Self-citationYasuda, K., Park, H. C., Ratliff, B. B., Addabbo, F., Hatzopoulos, A. K., Chander, P. N., & Goligorsky, M. S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091071 · Cited by 92
Coronary heart disease in Indians: Implications of the INTERHEART study
Ajay, V. S., & Prabhakaran, D. (2010) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.73396 · Cited by 90
Wang, X.-Y., Yang, C., Zheng, D., Mo, L., Lan, A., Yang, Z., Hu, F., Chen, P., Liao, X., & Feng, J. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1194-6 · Cited by 86
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. K. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00924.2012 · Cited by 85
Zordoky, B. N. M., Anwar‐Mohamed, A., Aboutabl, M. E., & El‐Kadi, A. O. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039123 · Cited by 85
Ondriaš, K., Borgatta, L., Kim, D. H., & Ehrlich, B. E. (1990) · Circulation Research · doi:10.1161/01.res.67.5.1167 · Cited by 85
Spallarossa, P., Altieri, P., Barisione, C., Passalacqua, M., Aloi, C., Fugazza, G., Frassoni, F., Podestà, M., Canepa, M., Ghigliotti, G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015583 · Cited by 83
Emerging role of epigenetics and miRNA in diabetic cardiomyopathy
Asrih, M., & Steffens, S. (2012) · Cardiovascular Pathology · doi:10.1016/j.carpath.2012.07.004 · Cited by 83
Koenig, J. S., Fischer, M., Bulant, E., Tiran, B., Elmadfa, I., & Druml, W. (1997) · PubMed · Cited by 83
Angelis, A. D., Piegari, E., Cappetta, D., Russo, R., Esposito, G., Ciuffreda, L. P., Ferraiolo, F. A. V., Frati, C., Fagnoni, F. F., Berrino, L., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.438 · Cited by 82
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
Bian, Y., Sun, M., Silver, M., Ho, K. K. L., Marchionni, M. A., Caggiano, A. O., Stone, J. R., Amende, I., Hampton, T., Morgan, J. P., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01010.2008 · Cited by 82
Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury
Gabrielson, K. L., Bedja, D., Pin, S., Tsao, A. L., Gama, L., Yuan, B., & Muratore, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3721 · Cited by 81
Inhibition of mitochondrial oxidative phosphorylation by adriamycin
Muhammed, H., Ramasarma, T., & Kurup, C. K. R. (1983) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(83)90155-x · Cited by 80
Antagonistic control of cell fates by JNK and p38-MAPK signaling
Wada, T., Stępniak-Konieczna, E., Hui, L., Leibbrandt, A., Katada, T., Nishina, H., Wagner, E. F., & Penninger, J. M. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402222 · Cited by 80
Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity
Jean, S. R., Tulumello, D. V., Riganti, C., Liyanage, S. U., Schimmer, A. D., & Kelley, S. O. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00268 · Cited by 79
Cardoso, S., Santos, R. X., Carvalho, C., Correia, S. C., Pereira, G. C., Pereira, S. P., Oliveira, P. J., Santos, M. S., Proença, T., & Moreira, P. I. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.08.008 · Cited by 77
Papadopoulou, L. C., Theophilidis, G., Thomopoulos, G. N., & Tsiftsoglou, A. S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00305-0 · Cited by 75
Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells
Chua, C. C., Liu, X., Gao, J., Hamdy, R. C., & Chua, B. H. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01138.2005 · Cited by 74
The Involvement of Lysosomes in Myocardial Aging and Disease
Terman, A., Kurz, T., Gustafsson, B., & BRUNK, U. T. (2008) · Current Cardiology Reviews · doi:10.2174/157340308784245801 · Cited by 70
Early changes in myocardial antioxidant enzymes in rats treated with adriamycin
Li, T., Danelisen, I., & Singal, P. K. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1014862912783 · Cited by 69
Adriamycin-activated macrophages as tumor growth inhibitors.
Js, H. (1981) · PubMed · Cited by 69
Cardiomyocyte autophagy and cancer chemotherapy
Li, D. ‘., & Hill, J. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.007 · Cited by 69
Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice
Vedam, K., Nishijima, Y., Druhan, L. J., Khan, M., Moldovan, N. I., Zweier, J. L., & Ilangovan, G. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01047.2009 · Cited by 69
Apoptosis During Regression of Cardiac Hypertrophy in Spontaneously Hypertensive Rats
Tea, B.-S., Dam, T.-V., Moreau, P. R., Hamet, P., & deBlois, D. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.229 · Cited by 69
Zhu, J., Zhang, J., Xiang, D., Zhang, Z., Zhang, L., Wu, M., Zhu, S., Zhang, R., & Han, W. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.06.024 · Cited by 67
Adriamycin-induced modulation of host defenses in tumor-bearing mice.
Maccubbin, D., Wing, K. R., Mace, K. F., et al. (1992) · PubMed · Cited by 65
Doxorubicin toxicity changes myocardial energy metabolism in rats
Wu, R., Wang, H., Yu, H., Cui, X., Xu, M.-T., Xu, X., & Gao, J. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.12.010 · Cited by 62
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy
Ranek, M. J., & Wang, X. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0068-8 · Cited by 61
Nordgren, K. K. S., & Wallace, K. B. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.10.023 · Cited by 56
Kwok, J. C., & Richardson, D. R. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.4.888 · Cited by 54
Doxorubicin Caused Apoptosis of Mesenchymal Stem Cells via p38, JNK and p53 Pathway
Yang, F., Chen, H., Liu, Y., Yin, K., Wang, Y., Li, X., Wang, G., Wang, S., Tan, X., Xu, C., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000354507 · Cited by 53
Doxorubicin-Mediated Cardiotoxicity: Role of Mitochondrial Connexin 43
Pecoraro, M., Sorrentino, R., Franceschelli, S., Pizzo, M. D., Pinto, A., & Popolo, A. (2014) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9305-8 · Cited by 52
Expression of p300 protects cardiac myocytes from apoptosis in vivo
Kawamura, T., Hasegawa, K., Morimoto, T., Iwai‐Kanai, E., Miyamoto, S., Kawase, Y., Ono, K., Wada, H., Akao, M., & Kita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.105 · Cited by 51
Acute Doxorubicin Cardiotoxicity
Pelikan, P. C. D., Weisfeldt, M. L., Jacobus, W. E., Miceli, M. V., Bulkley, B. H., & Gerstenblith, G. (1986) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198609000-00026 · Cited by 49
Tokarska-Schlattner, M., Lucchinetti, E., Zaugg, M., Kay, L., Gratia, S., Guzun, R., Saks, V. A., & Schlattner, U. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00360.2009 · Cited by 49
Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms?
Roca-Alonso, L., Pellegrino, L., Castellano, L., & Stebbing, J. (2012) · Cardiology · doi:10.1159/000339858 · Cited by 48
Goetzenich, A., Hatam, N., Zernecke, A., Weber, C., Czarnotta, T., Autschbach, R., & Christiansen, S. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.06.025 · Cited by 48
Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart
Park, A.-M., Nagase, H., Liu, L., Kumar, S. V., Szwergold, N. R., Wong, C., & Suzuki, Y. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq361 · Cited by 47
Akolkar, G., Bhullar, N., Bews, H. J., Shaikh, B., Premecz, S., Bordun, K.-A., Cheung, D. Y. C., Goyal, V., Sharma, A. K., Garber, P. J., et al. (2015) · Cardiovascular Ultrasound · doi:10.1186/s12947-015-0011-x · Cited by 47
de Tassigny, A. D., Souktani, R., Henry, P., Ghaleh, B., & Berdeaux, A. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00273.x · Cited by 46
The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study
Bahadır, A., Kurucu, N., Kadıoğlu, M., & Yeni̇lmez, E. (2013) · Turkish Journal of Hematology · doi:10.4274/tjh.2013.0013 · Cited by 44
Daunorubicin-DNA and doxorubicin-DNA a review of experimental and clinical data
Trouet, A., & Campeneere, D. D.-D. (1979) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253110 · Cited by 44
Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling
Holopainen, T., Ramste, M. O., Anisimov, A., Tuomainen, T., Zheng, W., Tvorogov, D., Hulmi, J. J., Andersson, L. C., Cenni, B., Tavi, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517810112 · Cited by 44
Sayed‐Ahmed, M. M. (2000) · Pharmacological Research · doi:10.1006/phrs.1999.0583 · Cited by 43
Neri, G. C., Neri, B., Bandinelli, M., Tacca, M. D., Danesi, R., & Riccardi, R. (2009) · Oncology · doi:10.1159/000226952 · Cited by 43
Doxorubicin has in vivo toxicological effects on ex vivo cultured mesenchymal stem cells
Barreto, M. S. O., Carvalho, J. L., Campos, A. C. D. A., Gomes, D. A., Goes, A. M., & Melo, M. M. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.11.023 · Cited by 43
UVRAG Deficiency Exacerbates Doxorubicin-Induced Cardiotoxicity
An, L. K., Hu, X., Zhang, S., Hu, X., Song, Z., Naz, A., Zi, Z., Wu, J., Li, C., Zou, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep43251 · Cited by 39
In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives
Praet, M., & Ruysschaert, J. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90027-w · Cited by 38
Gottar, M., Dodeller, F., Huesken, D., Iourgenko, V., Mickanin, C., Labow, M., Gaveriaux, S., Kinzel, B., Müeller, M., Alitalo, K. K., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002813 · Cited by 37
Loss of Bmx Nonreceptor Tyrosine Kinase Prevents Pressure Overload–Induced Cardiac Hypertrophy
Mitchell-Jordan, S. A., Holopainen, T., Ren, S. V., et al. (2008) · Circulation Research · doi:10.1161/circresaha.108.186577 · Cited by 37
Gu, R., Bai, J., Ling, L., Ding, L., Zhang, N., Ye, J., Ferro, A., & Xu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031279 · Cited by 33
Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity
Kim, D., Kim, H., Woo, E., Kwon, D., Kim, M., Chae, S., & Chae, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.045 · Cited by 32
Katamura, M. (2014) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000337 · Cited by 31
Iwasaki, T., & Suzuki, T. (1991) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02899525 · Cited by 26
Moriyama, T., Kemi, M., Okumura, C., et al. (2009) · Toxicology · doi:10.1016/j.tox.2009.12.004 · Cited by 25
Маркин, А. А., Popova, I. A., Vetrova, E. G., Zhuravleva, O. A., & Balashov, O. I. (1997) · PubMed · Cited by 24
Idris-Khodja, N., Marco, P. D., Farhat, M., Gény, B., & Schini‐Kerth, V. B. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/516017 · Cited by 11
Cited by
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M. K., Sung, P., Chen, J., & Weng, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14816 · Cited by 425
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2017 · Cited by 357
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Metadata
- Authors
- Renu, K., V.G., A., P.B., T. P., & Arunachalam, S.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 818
- Pages
- 241-253
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2766261199
- Cited by
- 588
- References
- 173
- FWCI
- 27.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.